News

Lisata Therapeutics Announces Upcoming Financial Results Event

Lisata Therapeutics Announces Upcoming Financial Results Event

Lisata Therapeutics Prepares for Financial Results Announcement

Lisata Therapeutics, Inc. (NASDAQ: LSTA), a clinical-stage pharmaceutical company making strides in innovative cancer therapies, is set to report its financial performance for the full year ending December 31, 2024. The announcement will occur on February 27, 2025, following the conclusion of market trading.

Details about the Upcoming Announcement

The company will provide insights into its financial status during a conference call scheduled for 4:30 p.m. Eastern Time on the same day. Participants interested in joining this call must pre-register via the designated link provided by the company. This step ensures they receive all necessary dial-in information and can seamlessly participate in the discussion.

What to Expect from Lisata Therapeutics

During the conference call, Lisata Therapeutics will likely share significant updates regarding its current projects and strategic direction, as well as address questions from investors. The anticipated release of the financial results marks a critical moment for the company, showcasing the progress it has made in clinical trials and product developments over the past year.

About Lisata's Innovative Therapies

Lisata Therapeutics is on the forefront of developing unique therapies targeting advanced solid tumors and other severe diseases. Their investigational treatment, certepetide, is designed to facilitate enhanced penetration of anti-cancer drugs directly into the tumors, potentially revolutionizing the treatment strategies available today.

What’s Next for Lisata Therapeutics?

Looking ahead, Lisata has ambitious plans for the coming years. The company aims to hit various milestones in its ongoing and upcoming clinical trials. With expectations of funding supporting operations into mid-2026, Lisata appears poised to deliver vital data that will inform both the market and its investors about product efficacy and safety.

Investor Relations

For inquiries regarding investment opportunities or investor relations, interested parties are encouraged to reach out to John Menditto, Vice President of Investor Relations at Lisata Therapeutics. He is available via phone or email, providing a direct line for any concerns or questions regarding the company's future prospects.

Frequently Asked Questions

When will Lisata Therapeutics report its financial results?

Lisata Therapeutics will report its financial results for the year ending December 31, 2024, on February 27, 2025.

How can investors participate in the conference call?

Investors can participate by registering through the link provided by Lisata Therapeutics to receive dial-in details.

What is certepetide?

Certepetide is an investigational drug developed by Lisata to enhance the targeted delivery of anti-cancer treatments to solid tumors.

Who can I contact for investor relations?

John Menditto, Vice President of Investor Relations, can be reached at Lisata Therapeutics for investor inquiries.

What are the company’s future plans?

Lisata Therapeutics plans to announce various milestones over the next 1.5 years, with funding anticipated to last until the second quarter of 2026.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 223

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading
LaserAway Expands to 244 Clinics Over 20 Years

Updated Category News Views 186

A Milestone in Aesthetic Dermatology Twenty years, folks. That's a long haul for most businesses, let alone one in the fickle field of aesthetic dermatology. LaserAway, the juggernaut in this arena, has just opened its 244th clinic at 6300 Kingery Hwy in Willowbrook, IL. Nothing to be sneezed at. Imagine running a business, let alone one that's been amping up aesthetic...

Continue Reading
Windward Bio Surges 68% in Nasdaq Debut

Updated Category News Views 206

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Continue Reading
WeFetch AI: A New Era in Barcode Precision

Updated Category News Views 201

WeFetch AI: What's in a Name? Forget about GreenCore Solutions Corp. We're talking about WeFetch AI Corp. now. They've just changed their name, fulfilling a bureaucratic tick as of November 13, 2026. But it ain't just a name change; it's a whole new ballgame in AI-driven commerce. AI Shopping Without the Guesswork We've all been there. You think you've ordered that...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 244

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Retirement Dreams Dashed: 61% Withdraw Early

Updated Category News Views 183

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 0

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
BETR's Slide: Investors Face Big Losses, Leadership Shift

Updated Category News Views 84

BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...

Continue Reading
Beko Pushes for Policy Synergy Amidst Carbon Shakeup

Updated Category News Views 166

When big names like Beko step up on the global stage, you pay attention. During the COP31 panels in Antalya, Türkiye, the company's brass made one thing clear: we need harmony in how climate, trade, and finance policies come together. The stakes? The very strength of industrial competitiveness as new carbon rules turn the heat up on manufacturing practices. The Call for...

Continue Reading
Manhattan Associates Faces Investigation by KSF Law Firm

Updated Category News Views 203

KSF Digs Into Manhattan Associates' Claims In the swirl of the financial world, you rarely see an investigation that doesn’t raise a few eyebrows. This time, it's Manhattan Associates, Inc. (NasdaqGS: MANH) squarely in the crosshairs of Kahn Swick & Foti, LLC (KSF), a pivotal player in securities litigation. You’ve got to wonder what dirt might be uncovered here,...

Continue Reading

Top 5 Most Recently Viewed Articles

Bertucci Investment Group: Earning Five-Star Results from Clients

Updated Category News Views 160

Bertucci Investment Group: Celebrating Success Bertucci Investment Group, known for facilitating smooth property sales for cash, is excited to share its significant achievement of earning consistent five-star reviews on Google. This milestone highlights the company’s dedication to providing an efficient and trustworthy service for homeowners. A Commitment to Excellence...

Continue Reading
Understanding Current Mortgage Rates and Refinancing Options

Updated Category News Views 98

Current Mortgage Rate Trends The 30-year mortgage rate has recently fallen to 5.93%, indicating a positive shift in the market compared to previous rates. This change is significant, as refinancing rates have also decreased substantially. These developments present opportunities for both new homebuyers and those looking to refinance their current loans. Current Mortgage...

Continue Reading
Market Reactions: Bitcoin Struggles Amid Rising Geopolitical Tensions

Updated Category News Views 55

Market Insights on Bitcoin's Challenges The narrative that Bitcoin operates as a safe haven during times of geopolitical tension has recently faced significant scrutiny. The leading cryptocurrency experienced a sharp decline, dropping below $62,000, amidst fears of escalating conflict in the Middle East. Bitcoin's Downturn As the situation escalated with reports of Iran's...

Continue Reading
Karsan's Autonomous Bus Debuts at Efteling Park

Updated Category News Views 100

A Leap Towards Autonomous Mobility What we have here is Karsan breaking new ground again. They've rolled out their Autonomous e-ATAK at Efteling, the famous theme park in the Netherlands. And that's not just any park—it's a place teeming with tourists, a hotspot demanding efficient transport. Yet, these folks aren't just cranking out fancy gadgets for showing off....

Continue Reading
Redfin's Strategic Shift as Mortgage Rates Begin to Fall

Updated Category News Views 91

The Mortgage Market and Its Impacts Recent shifts in U.S. mortgage rates have created significant waves in the real estate sector. The 30-year fixed mortgage rate recently hit 7.79%—the highest it’s been since 2000. This surge poses challenges for homeowners, many of whom are hesitant to sell their properties, worried they might sacrifice their favorable lower rates....

Continue Reading